Factors affecting the ability of patients with complex vascular anomalies to navigate the healthcare system
Source: Orphanet Journal of Rare Diseases
FDA Approval Summary: Alpelisib for PIK3CA-Related Overgrowth Spectrum
Source: Clinical Cancer Research
Errata regarding previously published articles (Chinese Journal of Plastic and Reconstructive Surgery (2022) 4(1) (28–30), (S2096691122000073), (10.1016/j.cjprs.2022.02.004))
Source: Chinese Journal of Plastic and Reconstructive Surgery
Work-Up and Treatment Strategies for Individuals with PIK3CA-Related Disorders: A Consensus of Experts from the Scientific Committee of the Italian Macrodactyly and PROS Association
Alpelisib for treatment of patients with PIK3CA-related overgrowth spectrum (PROS)
Source: Genetics in Medicine
For Patient Families
To support patients and caregivers, Elsevier Health is making the latest research on these rare disorders available upon request at no cost.
User acknowledges that these materials are provided for use at no charge as part of Elsevier’s efforts to support healthcare providers and patients. The information contained within the website is intended as a supplement to, and not a substitute for, the knowledge, expertise, skill and judgment of healthcare professionals involved in patient care. The content within this page may not be re-used, modified or re-distributed without prior written permission.
Cookies are used by this site. To decline or learn more, visit our cookie notice.
Copyright © 2024 Elsevier, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies.